DawMed Systems PLC
13 July 2005
DAWMED
13 July 2005
For immediate release:
DawMed Systems plc
('The Company')
Share Sale by Director
The Company has received notice pursuant to Section 324 of the Companies Act
1985 from one of its directors, John Crispin, that on 11 July 2005 and in order
to satisfy certain obligations relating to the divorce settlement with his
ex-wife, Mary Crispin, he sold 156,500 Ordinary Shares of 5p each in the capital
of the Company at a price of 16p per share.
Enquiries: Kevin Gilmore
Chairman
DawMed Systems plc 01789 450075
Roland Cornish
Chairman
Beaumont Cornish Limited 020 7628 3396
Dominic Barretto
Director
Bishopsgate Communications Ltd 020 7430 1600
This information is provided by RNS
The company news service from the London Stock Exchange
*A Private Investor is a recipient of the information who meets all of the conditions set out below, the recipient:
Obtains access to the information in a personal capacity;
Is not required to be regulated or supervised by a body concerned with the regulation or supervision of investment or financial services;
Is not currently registered or qualified as a professional securities trader or investment adviser with any national or state exchange, regulatory authority, professional association or recognised professional body;
Does not currently act in any capacity as an investment adviser, whether or not they have at some time been qualified to do so;
Uses the information solely in relation to the management of their personal funds and not as a trader to the public or for the investment of corporate funds;
Does not distribute, republish or otherwise provide any information or derived works to any third party in any manner or use or process information or derived works for any commercial purposes.
Please note, this site uses cookies. Some of the cookies are essential for parts of the site to operate and have already been set. You may delete and block all cookies from this site, but if you do, parts of the site may not work. To find out more about the cookies used on Investegate and how you can manage them, see our Privacy and Cookie Policy
To continue using Investegate, please confirm that you are a private investor as well as agreeing to our Privacy and Cookie Policy & Terms.